FDA Approves Novartis Kymriah CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular Lymphoma

Date: Fri, 27 May 2022 02:05:42 GMT
By: Drugs.com New Drug Approvals
Source: Drugs.com New Drug Approvals
Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings1.

“We are on a mission to build on our pioneering work in cell therapy and continue to innovate for patient impact.


Kymriah, the first approved CAR-T cell therapy, developed in collaboration with the Perelman School of Medicine at the University of Pennsylvania, is the foundation of the Novartis commitment to CAR-T cell therapy.

We continue to pioneer in cell therapy, leveraging our vast experience to develop next-generation CAR-T cell therapies.

The patient’s health care provider will do blood tests to check all their blood cell counts after treatment with KYMRIAH.

Wordcount: 108
Source:Drugs.com New Drug Approvals

Leave a Reply

Your email address will not be published. Required fields are marked *